203 related articles for article (PubMed ID: 17766835)
1. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
2. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
Beck JT; Hsu SM; Wijdenes J; Bataille R; Klein B; Vesole D; Hayden K; Jagannath S; Barlogie B
N Engl J Med; 1994 Mar; 330(9):602-5. PubMed ID: 8302342
[No Abstract] [Full Text] [Related]
3. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
4. Does IL-6 mediate renal manifestations of Castleman's disease?
Fujigaki Y; Hishida A
Intern Med; 2002 Dec; 41(12):1086-7. PubMed ID: 12521189
[No Abstract] [Full Text] [Related]
5. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
Newsom-Davis T; Bower M; Wildfire A; Thirlwell C; Nelson M; Gazzard B; Stebbing J
Leuk Lymphoma; 2004 Sep; 45(9):1939-41. PubMed ID: 15223659
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Disorders Associated with Castleman's Disease.
Kim HJ; Han JH; Bang CH; Park KS; Cho SG; Yoo DS; Kim KM; Park HJ; Park YM; Lee JY; Lee JH
Acta Derm Venereol; 2019 Oct; 99(11):984-989. PubMed ID: 31282978
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J; Maruyama I
Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
[TBL] [Abstract][Full Text] [Related]
9. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi Y; Tsuchimoto N
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
[No Abstract] [Full Text] [Related]
12. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
13. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
[TBL] [Abstract][Full Text] [Related]
14. Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions.
Mochizuki H; Kato M; Higuchi T; Koyamada R; Arai S; Okada S; Eto H
Intern Med; 2017; 56(9):1095-1099. PubMed ID: 28458319
[TBL] [Abstract][Full Text] [Related]
15. [Is there a place for interferon-alpha in the treatment strategy of multicentric Castleman's disease?].
Maloisel F; Andrès E; Campos F; Opréa C; Deslandres M; Randriamahazaka R; Kurtz JE; Koumarianou A; Dufour P
Rev Med Interne; 2000 May; 21(5):435-8. PubMed ID: 10874763
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
Arita Y; Sakata Y; Sudo T; Maeda T; Matsuoka K; Tamai K; Higuchi K; Shioyama W; Nakaoka Y; Kanakura Y; Yamauchi-Takihara K
Heart Vessels; 2010 Sep; 25(5):444-7. PubMed ID: 20676969
[TBL] [Abstract][Full Text] [Related]
17. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
Awano N; Inomata M; Kondoh K; Satake K; Kamiya H; Moriya A; Ando T; Kumasaka T; Takemura T; Takeuchi K; Ikushima S
Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
[TBL] [Abstract][Full Text] [Related]
18. Multicentric Castleman's disease in association with a solitary plasmacytoma: a case report.
Gould SJ; Diss T; Isaacson PG
Histopathology; 1990 Aug; 17(2):135-40. PubMed ID: 2227838
[TBL] [Abstract][Full Text] [Related]
19. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L
Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518
[TBL] [Abstract][Full Text] [Related]
20. Multicentric Castleman's disease in a Ghanaian adult.
Dei-Adomakoh YA; Segbefia C; Ekem I; Taylor A
Ghana Med J; 2013 Jun; 47(2):92-5. PubMed ID: 23966747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]